Clinical Trials Logo

Clinical Trial Summary

Highest treatment efficacy in patients with refractory myeloma may be achieved with regimens combining novel agents and alkylating agents. However, in applying this approach the patients are at substantial risks of a critical myelosuppression. Pomalidomide demonstrates significant activity in combination with Dexamethasone in relapsed or refractory multiple myeloma. This trial is an attempt to further improve the efficacy of Pomalidomide/Dexamethasone as well as to balance efficacy and toxicity. Integration of Cyclophosphamide in the treatment in case of suboptimal response or first evidence of progressive disease has the aim to significantly increase duration of treatment that should have a positive impact on PFS. It is furthermore an attempt to optimize the potential of Pomalidomide in the antimyeloma efficacy. Based on the recent findings, that myeloma is a disease with a wide clonal heterogeneity, combination treatment in case of suboptimal myeloma control might lead to a more effective suppression especially of aggressive subclones and might reduce early resistance. In addition, with the goal of keeping the individual patient as long as possible under an effective IMiD treatment, the potential of the drug might be optimized according to the current view of maintenance treatment resulting ideally in an outgrowth of indolent clones in the bone marrow niche.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02046915
Study type Interventional
Source University Hospital Tuebingen
Contact
Status Completed
Phase Phase 2
Start date April 2014
Completion date August 17, 2017

See also
  Status Clinical Trial Phase
Terminated NCT03837509 - INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Recruiting NCT05519085 - A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Phase 3
Active, not recruiting NCT02099539 - QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT00545519 - A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma Phase 1
Recruiting NCT05052970 - Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM Phase 1
Completed NCT03464916 - Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients Phase 1
Recruiting NCT05455320 - A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment Phase 3
Withdrawn NCT05408026 - Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM Phase 1/Phase 2
Not yet recruiting NCT06163040 - A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Recruiting NCT05652335 - A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis Phase 1
Completed NCT03859427 - A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Phase 3
Completed NCT01866293 - Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma Phase 1/Phase 2
Completed NCT01058434 - Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation Phase 2
Recruiting NCT04735575 - A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma Phase 1/Phase 2
Not yet recruiting NCT06298266 - To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma Early Phase 1
Recruiting NCT05572515 - A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Phase 3
Active, not recruiting NCT04798586 - MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma Phase 1
Terminated NCT02075021 - Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT00478777 - A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma Phase 3
Completed NCT06082596 - Study of BEBT-908 in Subjects With Advanced Hematological Tumors Phase 1